Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The role of pulmonary hypertension as a cause of mortality in sickle cell disease (SCD) is controversial. METHODS AND RESULTS: We evaluated the relationship between an elevated estimated pulmonary artery systolic pressure and mortality in patients with SCD. We followed patients from the walk-PHaSST screening cohort for a median of 29 months. A tricuspid regurgitation velocity (TRV)≥ 3.0 m/s cuttof, which has a 67-75% positive predictive value for mean pulmonary artery pressure ≥ 25 mm Hg was used. Among 572 subjects, 11.2% had TRV ≥ 3.0 m/sec. Among 582 with a measured NT-proBNP, 24.1% had values ≥ 160 pg/mL. Of 22 deaths during follow-up, 50% had a TRV ≥ 3.0 m/sec. At 24 months the cumulative survival was 83% with TRV ≥ 3.0 m/sec and 98% with TRV < 3.0 m/sec (p < 0.0001). The hazard ratios for death were 11.1 (95% CI 4.1-30.1; p < 0.0001) for TRV ≥ 3.0 m/sec, 4.6 (1.8-11.3; p = 0.001) for NT-proBNP ≥ 160 pg/mL, and 14.9 (5.5-39.9; p < 0.0001) for both TRV ≥ 3.0 m/sec and NT-proBNP ≥ 160 pg/mL. Age > 47 years, male gender, chronic transfusions, WHO class III-IV, increased hemolytic markers, ferritin and creatinine were also associated with increased risk of death. CONCLUSIONS: A TRV ≥ 3.0 m/sec occurs in approximately 10% of individuals and has the highest risk for death of any measured variable. The study is registered in ClinicalTrials.gov with identifier: NCT00492531.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with higher rates of hemolysis have lower steady-state Hb levels and are more likely to develop vascular injury and organ dysfunction as they age, manifesting as pulmonary hypertension, diastolic left heart disease, and renal dysfunction (proteinuria, albuminuria, and chronic kidney dysfunction) (62, 64, 65, 70, 79).”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NT-proBNP, a prepro hormone released from cardiac myocytes of the left and right ventricles in response to pressure overload and wall stress, also identifies patients at higher risk of having pulmonary hypertension, with lower exercise capacity and increased mortality risk.”
From Pathophysiology of Sickle Cell Disease (2019) · cites this paper as [62]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Self-citationRees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Self-citationACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Self-citationPulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Self-citationWriting Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Self-citationA Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease
Parent, F., Bachir, D., Inamo, J., Lionnet, F., Driss, F., Loko, G., Habibi, A., Bennani, S., Savale, L., Adnot, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005565 · Cited by 512
Pulmonary Complications of Sickle Cell Disease
Gladwin, M. T., & Vichinsky, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0804411 · Cited by 470
Self-citationMortality in Sickle Cell Disease
(1994) · New England Journal of Medicine · doi:10.1056/nejm199410133311515 · Cited by 459
Pulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298 · cited 2×
“We also observed associations with mortality for two separate biomarkers of pulmonary hypertension, TRV and NT-proBNP, both of which were identified as risk factors for death in other cohorts [3–5,13].”
BackgroundPulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease
Fonseca, G. H. H., Souza, R., Salemi, V. M. C., Jardim, C. V. P., & Gualandro, S. F. M. (2012) · European Respiratory Journal · doi:10.1183/09031936.00134410 · Cited by 274
Cited by
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Self-citationIntravascular hemolysis and the pathophysiology of sickle cell disease
Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89741 · Cited by 748
Self-citationSickle cell disease: renal manifestations and mechanisms
Nath, K. A., & Hebbel, R. P. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.8 · Cited by 369
Eapen, M., Brazauskas, R., Walters, M. C., Bernaudin, F., Bo-Subait, K., Fitzhugh, C. D., Hankins, J. S., Kanter, J., Meerpohl, J. J., Bolaños-Meade, J., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30154-1 · Cited by 206
Liem, R. I., Lanzkron, S., D. Coates, T., DeCastro, L., Desai, A. A., Ataga, K. I., Cohen, R. T., Haynes, J., Osunkwo, I., Lebensburger, J. D., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000916 · Cited by 182
Self-citationTherapeutic strategies for sickle cell disease: towards a multi-agent approach
Telen, M. J., Malik, P., & Vercellotti, G. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0003-2 · Cited by 181
Cardiovascular complications and risk of death in sickle-cell disease
Gladwin, M. T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00647-4 · Cited by 164
Self-citationLê, P. Q., Gulbis, B., Dedeken, L., Dupont, S., Vanderfaeillie, A., Heijmans, C., Huybrechts, S., Devalck, C., Efira, A., Dresse, M., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25608 · Cited by 164
Maitra, P., Caughey, M., Robinson, L., Desai, P. C., Jones, S., Nouraie, M., Gladwin, M. T., Hinderliter, A., Cai, J., & Ataga, K. I. (2017) · Haematologica · doi:10.3324/haematol.2016.153791 · Cited by 137
Self-citationPecker, L. H., & Lanzkron, S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202101190 · Cited by 112
Self-citationCardiovascular complications of sickle cell disease
Sachdev, V., Rosing, D. R., & Thein, S. L. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.02.002 · Cited by 92
Self-citationFitzhugh, C. D., Hsieh, M. M., Allen, D., Coles, W. A., Seamon, C., Ring, M., Zhao, X., Minniti, C. P., Rodgers, G. P., Schechter, A. N., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141706 · Cited by 64
“Recent studies reported no survival difference based on hydroxyurea use [16,18]; however, dosing was not mentioned.”
BackgroundSelf-citationCardiovascular complications in patients with sickle cell disease
Gladwin, M. T. (2017) · Hematology · doi:10.1182/asheducation-2017.1.423 · Cited by 64
Self-citationGellen, B., Messonnier, L. A., Galactéros, F., Audureau, É., Merlet, A. N., Rupp, T., Peyrot, S., Martin, C., Féasson, L., Bartolucci, P., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30163-7 · Cited by 59
Spann, A., Coe, C. L., Ajayi, T. A., Montgomery, G., Shwetar, M., Oje, A. O., Annis, J. S., Slaughter, J. C., Alexopoulos, S. P., Brittain, E. L., et al. (2022) · Liver Transplantation · doi:10.1002/lt.26460 · Cited by 59
Adams-Graves, P. E., & Bronté-Hall, L. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1180242 · Cited by 58
Heart Failure in Haemoglobinopathies: Pathophysiology, Clinical Phenotypes, and Management
Farmakis, D. T., Triposkiadis, F. K., Lekakis, J. P., & Parissis, J. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.708 · Cited by 58
How I treat the older adult with sickle cell disease
Thein, S. L., & Howard, J. (2018) · Blood · doi:10.1182/blood-2018-03-818161 · Cited by 57
Curtis, S. A., Danda, N., Etzion, Z., Cohen, H. W., & Billett, H. H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133116 · Cited by 53
Brazauskas, R., Scigliuolo, G. M., Wang, H.-L., Cappelli, B., Ruggeri, A., Fitzhugh, C. D., Hankins, J. S., Kanter, J., Meerpohl, J. J., Panepinto, J. A., et al. (2020) · Blood · doi:10.1182/blood.2020005687 · Cited by 50
Khan, S. A., Damanhouri, G. A., Ali, A., Khan, A. U., Khan, A., Bakillah, A., Marouf, S., Harbi, G. A., Halawani, S. H., & Makki, A. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0109-7 · Cited by 44
Hoppe, C. C., & Neumayr, L. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.014 · Cited by 44
Farrell, A. T., Panepinto, J. A., Desai, A. A., Kassim, A. A., Lebensburger, J. D., Walters, M. C., Bauer, D. E., Blaylark, R. M., DiMichele, D., Gladwin, M. T., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000883 · Cited by 44
Self-citationCaughey, M. C., Poole, C., Ataga, K. I., & Hinderliter, A. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13447 · Cited by 41
D’Alessandro, A., Nouraie, M. S., Zhang, Y., Cendali, F. I., Gamboni, F., Reisz, J. A., Zhang, X., Bartsch, K. W., Galbraith, M. D., Espinosa, J. M., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283288 · Cited by 39
Self-citationNouraie, M. S., Darbari, D. S., RANA, S. R., Minniti, C. P., Castro, O. L., Luchtman‐Jones, L., Sable, C., Dham, N., Kato, G. J., Gladwin, M. T., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25799 · Cited by 39
Self-citationSarode, R., Ballas, S. K., Garcia, A., Kim, H. C., King, K. E., Sachais, B. S., & Williams, L. A. (2016) · Journal of Clinical Apheresis · doi:10.1002/jca.21511 · Cited by 38
How I treat sickle cell disease with hematopoietic cell transplantation
Stenger, E. O., Shenoy, S. S., & Krishnamurti, L. (2019) · Blood · doi:10.1182/blood.2019000821 · Cited by 37
Self-citationHematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti, L. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2020.551170 · Cited by 37
Self-citationOnalo, R., Cilliers, A. M., Cooper, P., & Morris, C. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202108-1930oc · Cited by 37
Self-citationA phenotypic risk score for predicting mortality in sickle cell disease
Sachdev, V., Tian, X., Gu, Y., Nichols, J., Sidenko, S., Li, W., Beri, A., Layne, W. A., Allen, D. T., Wu, C. O., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17342 · Cited by 35
Self-citationD’Alessandro, A., Nouraie, M. S., Zhang, Y., Cendali, F. I., Gamboni, F., Reisz, J. A., Zhang, X., Bartsch, K. W., Galbraith, M. D., Gordeuk, V. R., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26923 · Cited by 35
Self-citationBiomarker signatures of sickle cell disease severity
Du, M., Ness, S. E. V., Gordeuk, V. R., Nouraie, M. S., Nekhai, S. A., Gladwin, M. T., Steinberg, M. H., & Sebastiani, P. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2018.05.001 · Cited by 34
Self-citationAmbient air pollution and sickle cell disease-related emergency department visits in Atlanta, GA
Blumberg, A. H., Ebelt, S., Liang, D., Morris, C. R., & Sarnat, J. A. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109292 · Cited by 33
Self-citationHemolysis and hemolysis‐related complications in females vs. males with sickle cell disease
Raslan, R., Shah, B. N., Zhang, X., Kanias, T., Han, J., Machado, R. F., Gladwin, M. T., Gordeuk, V. R., & Saraf, S. L. (2018) · American Journal of Hematology · doi:10.1002/ajh.25258 · Cited by 31
Self-citationChronic organ injuries in children with sickle cell disease
Allali, S., Taylor, M., Brice, J., & de Montalembert, M. (2021) · Haematologica · doi:10.3324/haematol.2020.271353 · Cited by 31
Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Sickle Cell Disease
Saraf, S. L., & Rondelli, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101565 · Cited by 29
Gondek, L. P., Sheehan, V., & Fitzhugh, C. D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113160 · Cited by 28
Heme Induces IL-6 and Cardiac Hypertrophy Genes Transcripts in Sickle Cell Mice
Gbotosho, O. T., Kapetanaki, M. G., Ghosh, S., Villanueva, F. S., Ofori-Acquah, S. F., & Kato, G. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01910 · Cited by 28
Self-citationThe Cardiopulmonary Complications of Sickle Cell Disease
Desai, A. A., Machado, R. F., & Cohen, R. T. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.07.014 · Cited by 25
Self-citationSachdev, V., Hsieh, M. M., Jeffries, N. O., Noreuil, A., Li, W., Sidenko, S., Hannoush, H., Limerick, E. M., Wilson, D., Tisdale, J. F., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000387 · Cited by 23
Self-citationThe role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
BUTROUS, G. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.42 · Cited by 22
Musa, B. M., Galadanci, N. A., Coker, M. O., Bussell, S. A., & Aliyu, M. H. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2693-z · Cited by 22
Fatores de risco para mortalidade em pacientes com doença falciforme: uma revisão integrativa
Pompeo, C. M., Cardoso, A. I. D. Q., Souza, M. D. C., Ferraz, M. B., Júnior, M. A. F., & Ivo, M. L. (2020) · Escola Anna Nery · doi:10.1590/2177-9465-ean-2019-0194 · Cited by 23
Daily pain in adults with sickle cell disease—a different perspective
Tuijn, C. F. J. V., Sins, J. W. R., Fijnvandraat, K., & Biemond, B. J. (2016) · American Journal of Hematology · doi:10.1002/ajh.24612 · Cited by 21
Gaartman, A. E., Sayedi, A. K., Gerritsma, J. J., de Back, T. R., Tuijn, C. F. J. V., Tang, M. W., Heijboer, H., de Heer, K., Biemond, B. J., & Nur, E. (2021) · British Journal of Haematology · doi:10.1111/bjh.17696 · Cited by 21
Rotz, S. J., O’Riordan, M. A., Kim, C., Langer, N., Cruz, C. M., Schilz, R. J., Lance, C. G., & Little, J. A. (2016) · American Journal of Hematology · doi:10.1002/ajh.24432 · Cited by 20
Self-citationClinical Manifestations of Sickle Cell Disease Across the Lifespan
Pecker, L. H., & Little, J. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62328-3_1 · Cited by 18
Self-citationOsteonecrosis of the Femoral Head: A Proposed New Treatment in Homozygous Sickle Cell Disease
Gatin, L., Rogier, A., Mary, P., Vialle, R., & Damsin, J.-P. (2016) · Hemoglobin · doi:10.3109/03630269.2015.1092159 · Cited by 18
Rotz, S. J., O’Riordan, M. A., Kim, C., Lima, M. J. G. D., Gladwin, M. T., & Little, J. A. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.11 · Cited by 18
Self-citationLiu, A., Jacobs, C., Sebastiani, P., Glassberg, J., McCuskee, S., & Curtis, S. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06253-w · Cited by 17
Yates, A. M., Joshi, V. M., Aygün, B., Moen, J., Smeltzer, M. P., Govindaswamy, D., Dowdy, J., Cotton, A., Kang, G., Ware, R. E., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27717 · Cited by 17
Curtis, S. A., Lew, D., Spodick, J., Hendrickson, J. E., Minniti, C. P., & Roberts, J. D. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002325 · Cited by 17
Hematopoietic cell transplantation for sickle cell disease: updates and future directions
Krishnamurti, L. (2021) · Hematology · doi:10.1182/hematology.2021000251 · Cited by 17
Self-citationA Growing Population of Older Adults with Sickle Cell Disease
Shet, A. S., & Thein, S. L. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.03.006 · Cited by 16
Shah, P., Suriany, S., Kato, R. M., Bush, A., Chalacheva, P., Veluswamy, S., Denton, C. C., Russell, K., Khaleel, M., Forman, H. J., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26003 · Cited by 16
Tavares, A. H. J., Benites, B. D., & Fertrin, K. Y. (2019) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2019.04.001 · Cited by 16
Honsel, V., Khimoud, D., Ranque, B., Offredo, L., Joseph, L., Pouchot, J., & Arlet, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122173 · Cited by 16
Shenoy, S. M., Kanter, J., Kassim, A. A., Fitzhugh, C. D., Stenger, E. O., Bhatia, M., Pecker, L. H., Krishnamurti, L., & King, A. A. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013953 · Cited by 15
Self-citationSavale, L., d’Humières, T., Boucly, A., Habibi, A., Lionnet, F., Loko, G., Inamo, J., Luna, G. D., Kahf, S. A., Chantalat‐Auger, C., et al. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202502-0353oc · Cited by 14
A reappraisal of the mechanisms underlying the cardiac complications of sickle cell anemia
Rai, P., Niss, O., & Malik, P. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26607 · Cited by 14
Schimmel, M., van Beers, E. J., Tuijn, C. F. J. V., Nur, E., Rijneveld, A. W., Gillavry, M. R. M., Brandjes, D. P. M., Schnog, J. B., Biemond, B. J., & on behalf of the CURAMA study group (2015) · American Journal of Hematology · doi:10.1002/ajh.23944 · Cited by 14
Limerick, E. M., & Abraham, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133856 · Cited by 13
Minireview: Prognostic factors and the response to hydroxurea treatment in sickle cell disease
Wang, W. C. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216642048 · Cited by 13
Jacob, S. A., Novelli, E. M., Isenberg, J. S., Garrett, M. E., Chu, Y., Soldano, K. L., Ataga, K. I., Telen, M. J., Ashley‐Koch, A. E., Gladwin, M. T., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24635 · Cited by 13
Self-citationShilo, N. R., & Morris, C. R. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1364989 · Cited by 13
Self-citationChatzidavid, S., Flevari, P., Tombrou, I., Anastasiadis, G., & Dimopoulou, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094792 · Cited by 12
Longitudinal Analysis of Patient Specific Predictors for Mortality in Sickle Cell Disease
Curtis, S. A., Danda, N., Etzion, Z., Cohen, H. W., & Billett, H. H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164743 · Cited by 12
Curtis, S. A., Balbuena-Merle, R. I., Roberts, J. D., Hendrickson, J. E., Starrels, J. L., Devine, L., DeVeaux, M., Daniel, Z., & Brandow, A. M. (2021) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2021.103304 · Cited by 12
Development and validation of the sickle cell stress scale‐adult
Smith, W. R., McClish, D. K., Bovbjerg, V. E., & Singh, H. K. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13789 · Cited by 12
Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy
Valeshabad, A. K., Wanek, J. M., Saraf, S. L., Gaynes, B. I., Gordeuk, V. R., Molokie, R. E., & Shahidi, M. (2015) · American Journal of Nephrology · doi:10.1159/000438678 · Cited by 12
Self-citationHuman genetics implicates a BACH2–NRF2 axis in fetal haemoglobin activation
Guo, C., Arora, U. P., Cheng, X., Xu, W., Cato, L. D., Li, R., Lu, H. Y., Lee, A., Yu, F., Agarwal, G., et al. (2026) · Nature · doi:10.1038/s41586-026-11113-2 · Cited by 11
Self-citationNouraie, M. S., Ashley‐Koch, A. E., Garrett, M. E., Sritharan, N., Zhang, Y., Little, J. A., Gordeuk, V. R., Gladwin, M. T., Telen, M. J., & Kato, G. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0237543 · Cited by 11
Self-citationThe different facets of sickle cell disease-related pulmonary hypertension
Prohaska, C. C., & Machado, R. F. (2021) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000795 · Cited by 11
Self-citationFang, F., Hazegh, K. E., Mast, A. E., Triulzi, D. J., Spencer, B. R., Gladwin, M. T., Busch, M. P., Kanias, T., & Page, G. P. (2022) · BMC Genomics · doi:10.1186/s12864-022-08461-4 · Cited by 10
Self-citationGarrett, M. E., Foster, M. W., Telen, M. J., & Ashley‐Koch, A. E. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00748 · Cited by 9
Homozygous sickle cell disease related mortality in Senegal (2011–2020)
Seck, M., Ba, O., Faye, B. F., Touré, S. A., Guèye, Y. B., Dieng, N., Sall, A., Gadji, M., Touré, A. O., & Diop, S. (2021) · eJHaem · doi:10.1002/jha2.273 · Cited by 9
Biomarkers and recent advances in the management and therapy of sickle cell disease
Telen, M. J. (2015) · F1000Research · doi:10.12688/f1000research.6615.1 · Cited by 9
Cardiac causes of hypoxia in sickle cell disease
Noronha, S. A. (2020) · Progress in Pediatric Cardiology · doi:10.1016/j.ppedcard.2019.101192 · Cited by 8
Almeida, L. E. F., Wang, L., Kamimura, S., Zerfas, P. M., Smith, M. L., Neto, O. L. A., Vale, T., Quezado, M., Horkayne‐Szakaly, I., Wakim, P., et al. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146968 · Cited by 8
Galadanci, N. A., Johnson, W. H., Carson, A. P., Hellemann, G. S., Howard, V. J., & Kanter, J. (2022) · Haematologica · doi:10.3324/haematol.2021.280480 · Cited by 8
miRNA profile and disease severity in patients with sickle cell anemia
Biassi, T. P., Guerra‐Shinohara, E. M., Moretti, P. N. S., Dutra, V. D. F., Cabañas‐Pedro, A. C., Mecabô, G., Colleoni, G. W. B., & Figueiredo, M. S. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04665-y · Cited by 8
Hersi, K., Ramani, G. V., Law, J. Y., Sadek, A. S., Vaidya, A., Gladwin, M. T., & Cassady, S. J. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12362 · Cited by 7
Self-citationDhédin, N., Paillard, C., Dalle, J., Ouachée-Chardin, M., Buchbinder, N., Brissot, É., Beguin, Y. P., Masouridi‐Levrat, S., Yakoub‐Agha, I., Bernit, E., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.06.003 · Cited by 7
Metabolic correlates to critical speed in murine models of sickle cell disease
Cendali, F. I., Nemkov, T. G., Lisk, C., LaCroix, I. S., Nouraie, M. S., Zhang, Y., Gordeuk, V. R., Buehler, P. W., Irwin, D. C., & D’Alessandro, A. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1151268 · Cited by 7
Self-citationEmerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations
Obadina, M. A., Wilson, S., Derebail, V. K., & Little, J. A. (2023) · Kidney360 · doi:10.34067/kid.0000000000000162 · Cited by 7
Self-citationDhabangi, A., Ainomugisha, B., Cserti-Gazdewich, C. M., Ddungu, H., Kyeyune, D., Musisi, E., Opoka, R. O., Stowell, C. P., & Dzik, S. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.01.007 · Cited by 7
Troponin Elevation in Sickle Cell Disease
Akkuş, N. İ., Rajpal, S., Hilbun, J., Dwary, A. D., Smith, T. R., Mina, G. S., & Reddy, P. C. (2021) · Medical Principles and Practice · doi:10.1159/000517540 · Cited by 7
Cheminet, G., Brunetti, A., Khimoud, D., Ranque, B., Michon, A., Flamarion, E., Pouchot, J., Jannot, A., & Arlet, J. (2023) · British Journal of Haematology · doi:10.1111/bjh.18777 · Cited by 6
Gene Therapies for Sickle Cell Disease
Weaver, S. B., Singh, D., & Wilson, K. M. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241268742 · Cited by 6
Exercise‐induced changes of vital signs in adults with sickle cell disease
Johnson, S., Gordeuk, V. R., Machado, R. F., Gibbs, J. S. R., Hildesheim, M. E., Little, J. A., Kato, G. J., Gladwin, M. T., & Nouraie, M. S. (2021) · American Journal of Hematology · doi:10.1002/ajh.26369 · Cited by 6
Self-citationKonté, K., Afzali‐Hashemi, L., Baas, K. P. A., Schrantee, A., Wood, J. C., Nur, E., Nederveen, A. J., & Biemond, B. J. (2024) · American Journal of Hematology · doi:10.1002/ajh.27522 · Cited by 5
Validation of a composite vascular high‐risk profile for adult patients with sickle cell disease
Nouraie, M. S., Little, J. A., Hildesheim, M. E., Gibbs, J. S. R., Morris, C. R., Machado, R. F., Kato, G. J., Gordeuk, V. R., & Gladwin, M. T. (2019) · American Journal of Hematology · doi:10.1002/ajh.25624 · Cited by 5
Self-citationNouraie, M. S., Zhang, X., Srisuwananukorn, A., Machado, R. F., Gordeuk, V. R., Gladwin, M. T., & Saraf, S. L. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201911-840rl · Cited by 5
Self-citationGhazaiean, M., Darvishi‐Khezri, H., Najafi, B., Karami, H., & Kosaryan, M. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318751 · Cited by 4
Gomaa, D. A., El-Haggar, S. M., El-Shanshory, M. R., Razaky, O. E., & El‐Afify, D. (2025) · Pediatric Drugs · doi:10.1007/s40272-025-00701-w · Cited by 4
Grazioli, A., Plazak, M. E., Willsey, K., Rabin, J., Rector, R. P., Belyayev, L. A., Lankford, A. S., Scalea, T. M., Shah, A. M., Taylor, B. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016368 · Cited by 4
Self-citationMusa, B. M., Odoh, C., Galadanci, N. A., Saidu, H., & Aliyu, M. H. (2018) · International Health · doi:10.1093/inthealth/ihx074 · Cited by 4
Hulbert, M. L., King, A. A., & Shenoy, S. S. (2022) · Hematology · doi:10.1182/hematology.2022000372 · Cited by 4
Identifying adolescent and young adult patients with sickle cell disease at highest risk of death
Gladwin, M. T., Kato, G. J., & Gordeuk, V. R. (2020) · American Journal of Hematology · doi:10.1002/ajh.26035 · Cited by 4
Self-citation
Metadata
- Authors
- Gladwin, M. T., Barst, R. J., Gibbs, J. S. R., Hildesheim, M., Sachdev, V., Nouraie, M., Hassell, K. L., Little, J. A., Schraufnagel, D. E., Krishnamurti, L., Novelli, E., Girgis, R. E., Morris, C. R., Berman Rosenzweig, E., Badesch, D. B., Lanzkron, S., Castro, O. L., Taylor, J. G., Goldsmith, J. C., Kato, G. J., Gordeuk, V. R., Machado, R. F., & on behalf of the walk-PHaSST Investigators and Patients
- Affiliations
- University of Pittsburgh (US)
- Columbia University (US)
- Imperial College London (GB)
- National Heart, Lung, and Blood Institute (US)
- Howard University (US)
- University of Colorado Denver (US)
- Case Western Reserve University (US)
- University of Illinois Chicago (US)
- Johns Hopkins University (US)
- Emory University (US)
- National Institutes of Health (US)
- Corresponding author
- Gladwin, Mark T.
- ORCID
- Gladwin, Mark T.
- Gibbs, J. Simon R.
- Sachdev, Vandana
- Nouraie, Mehdi
- Hassell, Kathryn L.
- Little, Jane A.
- Schraufnagel, Dean E.
- Krishnamurti, Lakshmanan
- Novelli, Enrico
- Girgis, Reda E.
- Morris, Claudia R.
- Lanzkron, Sophie
- Castro, Oswaldo L.
- Taylor, James G.
- Goldsmith, Jonathan C.
- Kato, Gregory J.
- Gordeuk, Victor R.
- Machado, Roberto F.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-07-02
- Volume
- 9
- Issue
- 7
- Pages
- e99489
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4079316
- OpenAlex
- W2121881033
- Cited by
- 132
- References
- 23
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 13 · 2020: 16 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 13 · 2015: 12 · 2014: 2
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- U.S. Department of Health and Human Services
- American Society of Hematology
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Gilead Sciences
- Ikaria
- United Therapeutics Corporation
- Bayer Corporation
- Hemophilia Center of Western Pennsylvania
- International Union Against Tuberculosis and Lung Disease
- National Institutes of Health
- U.S. Public Health Service (HHSN268200617182C)
- National Heart, Lung, and Blood Institute (P01HL103455, HHSN268200617182C, R01HL111656, K23HL083089)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- sickle cell disease, mortality risk factors, pulmonary hypertension, tricuspid regurgitation velocity, NT-proBNP, mean pulmonary artery pressure, survival, chronic transfusion, hemolysis, ferritin, creatinine
- MeSH terms
- Adult, Anemia, Sickle Cell, Blood Flow Velocity, Blood Pressure, Creatinine, Female, Ferritins, Follow-Up Studies, United Kingdom, Hemolysis, Humans, Hypertension, Pulmonary, Male, Middle Aged, Peptide Fragments, Risk Factors, Severity of Illness Index, United States, Cohort Studies, Proportional Hazards Models, Walking, Natriuretic Peptide, Brain, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.